Passage bio market cap
Web31 Mar 2024 · Passage Bio has 1 employees at their 1 location. See insights on Passage Bio including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Advanced. Products. ... Market Capitalization. $52.2 M. 2024-03-31. Passage Bio Summary. Company summary. Web15 Feb 2024 · Now, University of Pennsylvania professor James Wilson, one of the biggest names in gene therapy, has a startup of his own called Passage Bio. It has raised $115.5 million in series A financing to develop gene therapies for rare genetic diseases of the central nervous system.
Passage bio market cap
Did you know?
WebGet the latest Passage Bio Inc (PASG) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. WebFounded. 2024. Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for ...
Web18 Mar 2024 · Passage Bio Stock Price Today (NASDAQ: PASG) Quote, Market Cap, Chart WallStreetZen Passage Bio Inc Stock Add to Watchlist Overview Forecast Earnings … Web1 day ago · Passage Bio Inc. company and executive profile by Barron's. View the latest PASG company infomation and executive bios. ... Market Cap. Eli Lilly & Co. 0.71 % $312.04B. GSK PLC. 2.01 % £60.42B ...
WebSlon Capital. Oct 2006 - Present16 years 7 months. Investor & Founder. We have invested in several business since our last venture. Including 2 retailers. MCA operates 180 shops and restaurants in ... Web6 Apr 2024 · Passage Bio, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing transformative therapies for central nervous system (CNS) disorders. Its first product candidate, PBGM01, utilizes a AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal beta …
WebPassage Bio General Information. Description. Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, …
Web10 Dec 2024 · Passage Bio plans to report initial 30-day safety and biomarker data mid-year 2024 for Imagine-1. “GM1 is a devastating disease for patients and their families,” said Gary Romano, M.D., Ph.D., chief medical officer of Passage Bio. tie dyed sleeveless dresses with pocketsWeb1 May 2015 · Usala Consulting, Inc. May 2024 - Present5 years. Winterville, NC. Provide pharmaceutical, biologics, and medical device start-up, small and mid-size company consulting. • Chairman, Data Safety ... tiedyedsunflower aol.comWeb11 Feb 2024 · At Passage Bio (Nasdaq: PASG), we are on a mission to provide life-transforming genetic medicines for patients with CNS diseases that replace their suffering with boundless possibility, all... tie dyed sweaterWebPassage Bio finished 2024 with nearly $160 million in the bank but wasted no time coming back for more, filing earlier this month to raise $125 million in its IPO. Now, the gene … the manor house stafford cqcWebPassage Bio market cap history and chart from 2024 to 2024. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Passage Bio market cap as of March 17, 2024 is $0.06B. tie dyed sneakers for womenthe manor house skeyton road north walshamWeb1 Apr 2024 · Market Capitalization History of Passage Bio, Inc. Market capitalizations are calculated from the opening stock price at the beginning of each month. Top Competitors … tie dyed sunglasses